|
Difference in medians
|
|
NEq dosea, μg/kg/min
|
0.03 [0.01, 0.07]
|
0.04 [0.01, 0.16]
|
− 0.01 [− 0.06, 0.04]
|
0.17
|
|
Noradrenaline dosea, μg/kg/min
|
0.03 [0.01, 0.07]
|
0.05 [0.01, 0.15]
|
− 0.01 [− 0.06, 0.03]
|
0.08
|
|
Cumulative NEq dosea, μg/kg/48 h.
|
1.51 [0.51, 3.60]
|
2.14 [0.58, 7.78]
|
− 0.62 [− 3.18, 1.93]
|
0.19
|
|
Peak NEq dosea, μg/kg/min
|
0.12 [0.05, 0.20]
|
0.16 [0.08, 0.32]
|
− 0.03 [− 0.12, 0.06]
|
0.24
|
|
Change in NEq dose from baseline to peak levela, μg/kg/min
|
0.05 [0.01, 0.12]
|
0.05 [0.01, 0.14]
|
− 0.01 [− 0.06, 0.05]
|
0.61
|
|
Total duration of vasopressor supportb, h
|
51.6 [18.3, 99.7]
|
45.7 [19.6, 159.0]
|
3.1 [− 30.7, 36.9]
|
0.72
|
|
Survivors (n = 67)
|
35.6 [18.3, 69.4]
|
40.3 [22.2, 75.6]
|
− 3.5 [− 30.1, 23.1]
|
0.64
|
|
Non-survivors (n = 16)
|
186.0 [59.0, 311.0]
|
70.4 [19.4, 168.0]
|
19.8 [− 173.1, 212.6]
|
0.42
|
|
Duration of invasive ventilationb, days
|
2.2 [1.1, 5.9]
|
2.8 [1.2, 9.6]
|
− 0.5 [− 3.8, 2.8]
|
0.60
|
|
Hospital length of stayb, days
|
15.5 [9.4, 24.4]
|
13.2 [7.7, 21.0]
|
− 2.2 [− 8.5, 4.1]
|
0.30
|
|
ICU length of stayb, days
|
4.2 [2.7, 10.2]
|
4.7 [3.0, 11.3]
|
− 0.4 [− 3.4, 2.6]
|
0.67
|
|
Survivors (n = 67)
|
4.1 [3.0, 9.2]
|
4.3 [3.2, 7.0]
|
− 0.1 [− 2.7, 2.3]
|
0.70
|
|
Non-survivors (n = 16)
|
8.9 [2.4, 16.2]
|
8.3 [0.8, 11.3]
|
− 3.3 [− 16.2, 9.6]
|
0.87
|
|
Odds ratio (95% CI)
|
|
Patients alive and vasopressor-free at 48 h after randomization
|
20 (45.5)
|
18 (46.2)
|
0.97 (0.41–2.31)
|
0.95
|
|
ICU mortality
|
6 (13.6)
|
10 (25.6)
|
0.46 (0.15–1.41)
|
0.17
|
|
Hospital mortality
|
9 (20.5)
|
12 (30.8)
|
0.58 (0.21–1.57)
|
0.28
|
|
Day 90 mortality
|
12 (27.3)
|
13 (34.2)
|
0.72 (0.28–1.85)
|
0.50
|
